Evaluation of Plasma Fibrinogen Levels before and after Coronary Artery Bypass Graft Surgery and Its Association with the Need for Blood Products

Abstract

Background: The present study investigated the plasma level of fibrinogen before and after removing the pump in coronary artery bypass graft (CABG) surgery and its relationship with the need for blood products. Materials and Methods: The present study was performed on 60 patients who were candidates for CABG surgery. The fibrinogen level of these patients was assessed and recorded before surgery and immediately after removing the pump. In addition, their hemoglobin level was recorded before the operation and 2 h after. In addition, the number and type of blood products transfusion were recorded intraoperatively and postoperatively also at the intensive care unit. Results: Patients’ fibrinogen level after removing the pump with the mean of 130.53 ± 122.01 mg/dl decreased significantly compared to before surgery with the mean of mg/dl 224.95 ± 132.88 mg/dl (P < 0.001). In addition, the prognostic value of fibrinogen after removing the pump in determining the postoperative need of blood transfusion showed that the cut-off value of fibrinogen was < 196 mg/dl with a sensitivity of 16.82% and specificity of 80%, but it was not statistically significant (area under the curve [95% confidence interval]: 0.519 [0.350–0.689]; P = 0.825). Conclusion: According to the results of the present study, due to significant changes in fibrinogen levels after removing the pump compared to preoperation, it seems that this factor can play an important role in prognosis of the need to postoperative blood transfusion, although the prognostic value and the critical point mentioned in our study was not significant and it is required to do further studies.

Keywords: Blood Transfusion, Coronary Artery Bypass Grafting, fibrinogen

Introduction

Transfusion of blood and blood products is a significant portion of cardiac surgery.[1] Although 15%–20% of patients require cardiac surgery, more than 80% of blood products are consumed in this type of surgery.[2] In fact, the inherent feature of the cardiovascular surgery, especially when cardiopulmonary bypass (CPB) is involved in the occurrence of frequent bleedings during and after surgery, so that postoperative bleeding is a life-threatening complication in 5%–25% of cases. Therefore, the need for injecting blood products during and after surgery is inevitable.[3]

Therefore, as the prescription of blood products increases the risk of adverse outcomes, affects the patient outcome, and will also be associated with increased medical costs,[4] it is preferable to avoid blood transfusion, and researchers aim at figuring out a way to minimize the need for blood products or to provide the required prognosis to prevent bleeding.[5,6]

Bleeding during the cardiac surgery may be influenced by patient-related factors and procedures, the use of anticoagulants, inflammation, consumption and dilution, clotting factors, and fibrinolysis associated with the use of CPB.[7] The substitution of major blood loss with red blood cells and colloid fluids leads to the development of plasma fibrinogen deficiency earlier than any other clotting factors,[8] which may, in turn, result in the excessive postoperative blood loss that requires transfusion of blood products.[9,10]

Therefore, fibrinogen seems to be the main risk factor for bleeding, modulates platelet aggregation, and determines medical costs.[4] It is preferable to avoid blood transfusion, and researchers aim at figuring out a way to minimize the need for blood products or to provide the required prognosis to prevent bleeding.[5,6]

Address for correspondence:
Azim Honarmand, Keivan Bagheri, Alireza Hoghooghy, Kazem Rezaei
Department of Anesthesiology, Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
E-mail: alireza.hoghooghy@gmail.com

Received: 31 January 2021
Revised: 15 April 2021
Accepted: 03 May 2021
Published: 30 March 2022

Access this article online
Website: www.advbiores.net
DOI: 10.4103/abr.abr_22_21

How to cite this article: Honarmand A, Bagheri K, Hoghooghy A, Rezaei K. Evaluation of plasma fibrinogen levels before and after coronary artery bypass graft surgery and its association with the need for blood products. Adv Biomed Res 2022;11:25.
plasma viscosity. Fibrinogen is an acute-phase reactant, is synthesized in the liver, increases in inflammatory states, and mediates the thrombogenic effect of other risk factors. Elevated fibrinogen levels lead to the increased coagulation activity and are associated with increased cardiovascular disorders, atherosclerosis, peripheral vascular disease, and other thromboembolisms.

However, little clinical information is available on the association of fibrinogen levels before and after CABG surgery with bleeding and the nontransfusion of blood products. Therefore, the present study aimed at investigating the association between plasma fibrinogen levels before and after CABG surgery with the need for blood products.

Materials and Methods

The present study was a cross-sectional study. The study population was all patients that were candidates for open-heart surgery with the coronary artery bypass grafting (CABG) type in Chamran Hospital of Isfahan, Iran, during 2018–2019. The sample size was estimated to be 60 patients at the confidence level of 95%, test power of 80%, and the association of 0.35 between fibrinogen and the need for blood products. The sample was randomly selected from eligible patients meeting the inclusion criteria.

Inclusion criteria included being a candidate for CABG and over 18-year-old. If the patient had a prediagnosed coagulation disorder (a disorder that leads to the need for injecting anticoagulants, fresh frozen plasmas, platelets, or coagulation factors), they were not included in the study.

After obtaining the code of ethics from the Ethics Committee of Isfahan University of Medical Sciences (Code: IR. MUI. MED. REC.1399.171) and obtaining written consent from patients, demographic information of patients such as age, sex, weight, and comorbidities were recorded at the beginning of the study. In addition, fibrinogen and hemoglobin levels were assessed and recorded before the surgery. The use of inotropic, the duration of anesthesia, the time of CPB, and the number and type of blood products injected during surgery were also recorded. Moreover, the patients' fibrinogen level was measured immediately after off-pump CABG.

CABG was then performed for all patients. The number and type of injected blood products, the duration of anesthesia, the duration of intensive care unit (ICU), and the duration of ventilation were recorded after the surgery. Blood samples were taken from each patient 2 h after the surgery, and their hemoglobin level was measured again.

Finally, the data collected were entered into the Statistical Package for Social Sciences software (SPSS 23 for Windows; SPSS, Chicago, IL, USA). The data were presented as means ± standard deviation or n (%). At the level of inferential statistics, Mann–Whitney test was used to compare the mean of fibrinogen in transfused and nontransfused patients. Moreover, the Wilcoxon test was used to compare the mean of fibrinogen after off-pump CABG as compared to before the surgery. Finally, receiver operating characteristic (ROC) analysis was employed to achieve the prognostic value of the fibrinogen level in determining the need for blood products after the surgery and determining the area under the curve (AUC) indicators, sensitivity and specificity, positive predictive value (PPV), and negative predictive value (NPV). In all analyses, a significance level of <0.05 was considered.

Results

In the present study, out of 60 patients undergoing open-heart CABG surgery with a mean age of 63.80 ± 9.82 years, 44 (73.3%) and 16 (26.7%) patients were male and female, respectively. Forty nine (81.7%) and 44 (73.3%) patients were in need of blood products during and after the surgery (in ICU), respectively. The number of blood product units required was 3–8. Other baseline and clinical characteristics of patients are presented in Tables 1 and 2.

Patients’ fibrinogen level significantly decreased after off-pump CABG with a mean of 130.53 ± 122.01 mg/dl as compared with before surgery with a mean of 224.95 ± 132.88 mg/dl (P < 0.001). However, the fibrinogen level was not significantly different before and after the intervention between transfused and nontransfused patients (P > 0.05) [Figure 1].

Moreover, the need for blood products before and after the surgery did not differ significantly by patients’ gender and age (P > 0.05) [Table 3].

In addition, there was no significant difference in the decreased fibrinogen level after the off-pump CABG as compared to before the surgery by patients’ gender, age, comorbidities, and smoking (P > 0.05) [Table 4].

![Figure 1: Comparison of the mean fibrinogen level based on the need to receive blood products](image-url)
Finally, ROC analysis in identifying the prognostic value of fibrinogen after the off-pump CABG in determining the need of blood products after the surgery revealed the cut-off value of fibrinogen <196 mg/dl with the sensitivity of 16.82% and specificity of 80%, the PPV of 70%, and the NPV of 26%. However, it must be mentioned that the reported cut-off point was not statistically significant (AUC [95% confidence interval (CI)]: 0.519 [0.350–0.689]; \( P = 0.825 \)) [Table 5].

### Discussion

The results of the present study revealed that the transfusion rate of blood products (between 3 and 8 units) during and after the surgery was more than 70%. The study patients did not have anemia before the surgery, and their coagulation factors and fibrinogen levels were normal.

In this regard, Elmistekawy et al. reported that 67.6% and 13.3% of patients received more than 2 and 4 units of packed red blood cells (PRBC).\(^{[13]}\) Another study indicated that 12% of patients received more than 3 units, and 48% of patients received between 1 and 3 units of PRBC.\(^{[14]}\) Based on the results of previous studies, many factors such as the presence of anemia before surgery, aging, and decreased levels of hemoglobin, hematocrit, and

### Table 1: Baseline and clinical characteristics of the study group

| Characteristics | Mean±SD or n (%) |
|-----------------|------------------|
| Sex             |                  |
| Male            | 44 (73.3)        |
| Female          | 16 (26.7)        |
| Age (year)      | 63.80±9.82       |
| Weight (kg)     | 73.03±12.82      |
| EF (%)          | 47.67±10.63      |
| Comorbidities   |                  |
| Diabetes        | 25 (41.7)        |
| Hypertension    | 28 (46.7)        |
| Hyperlipidemia  | 10 (16.7)        |
| Other           | 1 (8.3)          |
| Smoking         | 11 (18.3)        |
| Opioid use      | 8 (13.3)         |
| Used inotropes  |                  |
| Dopamine        | 0                |
| Dobutamine      | 7 (11.7)         |
| Epinephrine     | 11 (18.3)        |
| Norepinephrine  | 10 (16.7)        |

EF: Ejection fraction, SD: Standard deviation

### Table 2: Surgery-related variables of the study group

| Variables                        | Mean±SD or n (%) |
|----------------------------------|------------------|
| HB before surgery (g/dl)         | 13.74±1.77       |
| HB after surgery (g/dl)          | 9.51±1.13        |
| Blood products during surgery    | 49 (81.7)        |
| Type of blood products during surgery |              |
| PC                               | 1.23±0.87        |
| FFP                              | 0.72±1.89        |
| PLT                              | 0.68±1.72        |
| Blood products after surgery     | 44 (73.3)        |
| Type of blood products after surgery |            |
| PC                               | 1.52±1.35        |
| FFP                              | 0.63±1.49        |
| PLT                              | 0.35±1.27        |
| Surgery duration (h)             | 3.96±0.68        |
| Duration of anesthesia (h)       | 4.83±0.67        |
| Time of CPB (min)                | 80.05±37.73      |
| ICU duration (day)               | 3.44±1.30        |
| Duration of ventilation (day)    | 12.23±7.96       |

HB: Hemoglobin, CPB: Cardiopulmonary bypass, SD: Standard deviation, PLT: Platelet, ICU: Intensive care unit, PC: Platelet concentrate, FFP: Fresh-frozen plasma

### Table 3: Frequency distribution of the need for blood products before and after surgery by patients’ gender and age

| Factors | Blood products before surgery, \( n \) (%) | Blood products after surgery, \( n \) (%) | \( P \) |
|---------|------------------------------------------|--------------------------------------|-------|
| Sex     |                                          |                                      |       |
| Male    | 34 (69.4)                                | 33 (75.0)                            | 0.628 |
| Female  | 15 (30.6)                                | 11 (25.0)                            |       |
| Age (years) |                                      |                                      |       |
| <40     | 2 (4.1)                                  | 2 (4.6)                              | 0.137 |
| 40-50   | 2 (4.1)                                  | 0                                     |       |
| 50-60   | 13 (26.5)                                | 14 (31.8)                            |       |
| 60-70   | 22 (44.9)                                | 18 (40.9)                            |       |
| >70     | 10 (20.4)                                | 10 (22.7)                            |       |

### Table 4: Mean of decreased fibrinogen level after the off-pump coronary artery bypass graft as compared to before the surgery by patients’ baseline and clinical characteristics

| Factors            | Decreased fibrinogen | \( P \) |
|--------------------|----------------------|-------|
| Sex                |                      |       |
| Male               | \(-128.82±133.58\)   | 0.327 |
| Female             | \(-166.31±118.52\)   |       |
| Age (years)        |                      |       |
| <40                | \(-260.00±188.09\)   | 0.955 |
| 40-50              | \(-164.00±113.1\)    |       |
| 50-60              | \(-121.18±118.02\)   |       |
| 60-70              | \(-117.68±129.75\)   |       |
| >70                | \(-176.54±148.46\)   |       |
| Comorbidities      |                      |       |
| Diabetes (\( n=25 \)) | \(-122.52±139.64\)  | 0.416 |
| Hypertension (\( n=28 \)) | \(-128.78±113.9\)  |       |
| Hyperlipidemia (\( n=10 \)) | \(-171.30±88.2\) |       |
| Other (\( n=5 \)) | \(-25.6±92.34\)     |       |
| Smoking            |                      |       |
| Yes                | \(-86.73±82.12\)    | 0.054 |
| No                 | \(-150.51±136.21\)  |       |
According to previous studies, plasma fibrinogen levels below 200 mg/dl may be associated with an increased risk of postoperative bleeding after cardiac surgery. CPB during surgery causes a significant drop in plasma fibrinogen levels, which in turn will lead to the excessive postoperative bleeding.\textsuperscript{[22,23]}

In the present study, the cut-off point of fibrinogen level after the pump-off CABG in the prognosis of bleeding 2 h after the surgery was <196 mg/dl with the sensitivity and specificity of 16.50% and 80%, respectively.

In a large sample size study, Karkouti \textit{et al.} indicated that the probability of a large volume transfusion at the fibrinogen level of <200 mg/dl increased with a sensitivity of 50% and specificity of 60% such that 42% of patients had less than this fibrinogen level and 18.9% of patients with the mentioned fibrinogen level had a large volume transfusion as compared to patients with the fibrinogen level of more than 200 mg/dl.\textsuperscript{[24]}

Alagha \textit{et al.} also revealed that preoperative plasma fibrinogen concentration of <3.1 g/l was significantly associated with an increased risk of excessive bleeding in patients undergoing on-pump CABG.\textsuperscript{[21]} Although this study did not examine the association between fibrinogen levels before surgery and transfusion of intraoperative and postoperative blood products, many underlying factors may affect bleeding surgery or the need for postoperative blood products. Therefore, the consideration of fibrinogen levels before surgery may not be very reliable.

The current study also paid due attention to the fibrinogen level after pump-off CABG in the prognosis of bleeding after surgery. Although the reported cut-off point was not statistically significant, its PPV was 70% and accurately warned of the increased likelihood of the transfusion blood products in study patients.

Cut-off values ranging from 1.44 to 2.85 g/l have been established in a number of studies addressing the best combination of specificity and sensitivity to describe the postoperative fibrinogen level linked to bleeding.\textsuperscript{[25-27]}

In this regard, the cut-off value of 2.2 g/l, sensitivity of 67%, and specificity of 57% have been reported by Kindo \textit{et al.} However, the evaluation of a PPV can be considered as a more acceptable estimation of trigger values the supplementation of fibrinogen in case of excessive bleeding.\textsuperscript{[24,10]} Ranucci \textit{et al.} reported that the fibrinogen level of 1.15 g/l yielded a PPV of 50%.\textsuperscript{[28]}

Finally, it is important to note that the assessment of fibrinogen levels before surgery, after the pump-off CABG, or after surgery in the prognosis of the need for blood products by consideration of the gender or age of patients could be significant and interesting; however, the present study did not obtain valuable results because of the small sample size. In addition, as previous studies have examined the association between fibrinogen levels and bleeding.

| Table 5: The prognostic value of fibrinogen after off-pump in determining the need of blood products |
|-----------------------------------------------|
| Parameters of ROC analysis | Fibrinogen after off-pump (mg/dl), % (95% CI) |
|-----------------------------------------------|
| AUC                                           | 0.519 (0.350-0.689) |
| $P$                                           | 0.825 |
| Cut-off point                                 | <196 |
| Sensitivity                                   | 16.82 (4.55-38.64) |
| Specificity                                   | 80.00 (54.40-94.00) |
| PPV                                           | 70.00 (34.80-93.31) |
| NPV                                           | 26.00 (14.64-40.36) |

ROC: Receiver operating characteristic, AUC: Area under curve, PPV: Positive predictive value, NPV: Negative predictive value, CI: Confidence interval
during and after surgery, this study examined the need for blood products, which is directly related to bleeding, with a different perspective that can be regarded as one of the strengths of this study because calculating the volume of bleeding, especially during surgery can be difficult and erroneous and may not be accurate enough. Finally, it is suggested that future studies with larger sample sizes assess the level of fibrinogen after the pump-off CABG with bleeding or the need for blood products after surgery so that the results can be more confidently generalized to the target population.

**Conclusion**

According to the results of the present study, the fibrinogen level after the pump-off CABG as compared to before the surgery significantly reduced. In addition, the fibrinogen cut-off point in the prognosis of the need to receive blood products after the surgery was found to be less than 196 mg/dl with a high PPV and specificity though it was not statistically significant.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Brouwers C, Hoofman B, Vonk S, Vonk A, Stooker W, Te Gussinklo WH, et al. Benchmarking the use of blood products in cardiac surgery to stimulate awareness of transfusion behaviour: Results from a four-year longitudinal study. Neth Heart J 2017;25:207-14.

2. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, et al. 2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011;91:944-82.

3. Williams ML, He X, Rankin JS, Slaughter MS, Gammie JS. Preoperative hematocrit is a powerful predictor of adverse outcomes in coronary artery bypass graft surgery: A report from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 2013;96:1628-34.

4. Christensen MC, Dziewior F, Kempel A, von Heymann C. Increased chest tube drainage is independently associated with adverse outcome after cardiac surgery. J Cardiothorac Vasc Anesth 2012;26:46-51.

5. Möhle P, Snyder-Ramos SA, Miao Y, Kulier A, Böttiger BW, Levin J, et al. Postoperative red blood cell transfusion and morbidity in uncomplicated cardiac surgery patients. Intensive Care Med 2011;37:97-109.

6. Ranucci M, Baryshnikova E, Castelvecchio S, Pelissero G, Surgical and Clinical Outcome Research (SCORE) Group. Major bleeding, transfusions, and anemia: The deadly triad of cardiac surgery. Ann Thorac Surg 2013;96:478-85.

7. Karkouti K, McCluskey SA, Syed S, Pazaratc Z, Poonawala H, Crowther MA. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: A prospective observational study. Anaesth Analg 2010;110:1533-40.

8. Bilecen S, de Groot JA, Kalkman CJ, Spanjersberg AJ, Brandon Bravo Bruinsma GJ, Moons KG, et al. Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: A randomized clinical trial. JAMA 2017;317:738-47.

9. Walden K, Jeppsson A, Nasic S, Backlund E, Karlsson M. Low preoperative fibrinogen plasma concentration is associated with excessive bleeding after cardiac operations. Ann Thorac Surg 2014;97:1199-206.

10. Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, et al. Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. Thromb Res 2014;134:360-8.

11. Pieters M, Wolberg AS. Fibrinogen and fibrin: An illustrated review. Pract Thromb Haemost 2019;3:161-72.

12. Naji DH, Tan C, Han F, Zhao Y, Wang J, Wang D, et al. Significant genetic association of a functional TFPI variant with circulating fibrinogen levels and coronary artery disease. Mol Genet Genomics 2018;293:119-28.

13. Elmistetakwy EM, Errett L, Fawzy HF. Predictors of packed red cell transfusion after isolated primary coronary artery bypass grafting – The experience of a single cardiac center: A prospective observational study. J Cardiothorac Surg 2009;4:20.

14. Galas FR, Almeida JP, Fukushima JT, Osawa EA, Nakamura RE, Silva CM, et al. Blood transfusion in cardiac surgery is a risk factor for increased hospital length of stay in adult patients. J Cardiothorac Surg 2013;8:54.

15. Greinacher A, Fendrich K, Hoffmann W. Demographic changes: The impact for safe blood supply. Transfus Med Hemother 2010;37:141-8.

16. Likosky DS, Paugh TA, Harrington SD, Wu X, Rogers MA, Dickinson TA, et al. Prediction of transfusions after isolated coronary artery bypass grafting surgical procedures. Ann Thorac Surg 2017;103:764-72.

17. Mazlan AM, Ayob Y, Hussein AR, Namaswayam TK, Wan Mohammad WM. Factors influencing transfusion requirement in patients undergoing first-time, elective coronary artery bypass graft surgery. Asian J Transfus Sci 2017;11:95-101.

18. Frankel TL, Stamou SC, Lowery RC, Kapetanakis EI, Hill PC, Haile E, et al. Risk factors for hemorrhage-related reexploration and blood transfusion after conventional versus coronary revascularization without cardiopulmonary bypass. Eur J Cardiothorac Surg 2005;27:494-500.

19. Karlsson M, Ternström L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: A prospective observational study. J Cardiothorac Surg 2008;4:215-22.

20. Solomon C, Pichlmaier U, Schoechl H, Hagi C, Raymonds K, Scheinichen D, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010;104:555-62.

21. Alagha S, Songur M, Avci T, Vural K, Kaplan S. Association of preoperative plasma fibrinogen level with postoperative bleeding after on-pump coronary bypass surgery: Does plasma fibrinogen level affect the amount of postoperative bleeding? Interact Cardiovasc Thorac Surg 2018;27:671-6.
fibrinogen replacement therapy remains uncertain. J Thromb Haemost 2013;11:1519-26.
23. Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: A randomized, placebo-controlled trial. Anesthesiology 2013;118:40-50.
24. Karkouti K, Callum J, Crowther MA, McCluskey SA, Pendergrast J, Tait G, et al. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: An observational study. Anesth Analg 2013;117:14-22.
25. Wikkelsø A, Lunde J, Johansen M, Stensballe J, Wetterslev J, Möller AM, et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev 2013;8:1-89.
26. Ranucci M, Pistuiddi V, Baryshnikova E, Colella D, Bianchi P. Fibrinogen levels after cardiac surgical procedures: Association with postoperative bleeding, trigger values, and target values. Ann Thorac Surg 2016;102:78-85.
27. Erdoes G, Koster A, Meesters MI, Ortmann E, Bolliger D, Baryshnikova E, et al. The role of fibrinogen and fibrinogen concentrate in cardiac surgery: An international consensus statement from the Haemostasis and Transfusion Scientific Subcommitiee of the European Association of Cardiothoracic Anaesthesiology. Anaesthesia 2019;74:1589-600.
28. Ranucci M, Jepsson A, Baryshnikova E. Pre-operative fibrinogen supplementation in cardiac surgery patients: An evaluation of different trigger values. Acta Anaesthesiol Scand 2015;59:427-33.